Liver cirrhosis (Q87200165)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Liver cirrhosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Andrew Kenneth Burroughs

series ordinal

3

object named as

Andrew K Burroughs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

2

Jaime Bosch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

28 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

9930

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

1749-1761

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The burden of liver disease in Europe: a review of available epidemiological data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Functional aspects on the pathophysiology of portal hypertension in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Transjugular liver biopsy: how good is it for accurate histological interpretation?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Noninvasive methods to assess liver disease in patients with hepatitis B or C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Renal failure and cirrhosis: a systematic review of mortality and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Developing a 'traffic light' test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Excess weight risk factor for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

New therapeutic paradigm for patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Clearing the smoke in chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Association of coffee drinking with total and cause-specific mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Is it time to write a prescription for coffee? Coffee and liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Review article: prescribing medications in patients with cirrhosis - a practical guide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Impact of obesity on treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hepatic venous pressure gradient in 2010: optimal measurement is key

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Incidence and natural history of small esophageal varices in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Management of varices and variceal hemorrhage in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Total effective vascular compliance in patients with cirrhosis. Effects of propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Carvedilol for portal hypertension in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Primary prevention of variceal haemorrhage: a pharmacological approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Bacterial infection in the pathogenesis of variceal bleeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Transfusion strategies for acute upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Early use of TIPS in patients with cirrhosis and variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Management of adult patients with ascites due to cirrhosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Infection, coagulation, and variceal bleeding in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Evidence of neutrophil functional defect despite inflammation in stable cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in patients with decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Restricted use of albumin for spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Clostridium difficile is associated with poor outcomes in patients with cirrhosis: A national and tertiary center perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Rifaximin treatment in hepatic encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Rifaximin Improves Driving Simulator Performance in a Randomized Trial of Patients With Minimal Hepatic Encephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Cognitive dysfunction in cirrhosis is associated with falls: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Prolonging survival in patients with cirrhosis: old drugs with new indications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Hemostasis and thrombosis in patients with liver disease: the ups and downs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Systematic review: portal vein thrombosis in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960121-5

7 January 2021

10.1016/S0140-6736(14)60121-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24480518%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference